Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Insulin Pills

27.02.2002


The issue of insulin-dependent diabetes has long been discussed. No wonder, as the problem concerns more than 5% of the world population. However, despite the enormous efforts and funds spent on its solution, the scientists so far have failed to replace the injections with pills. The difficulty is that insulin (like any other polypeptide) gets easily destroyed under the influence of proteolytic enzymes in the stomach and small intestines. The scientists have tried a variety of means: insulin plasters, inhalations, capsules covered with a special protective coating, but none of the above has ensured the required effect. The amount of insulin thus getting into the blood is insufficient for normal functioning of the organism.



Chemists from the the Topichev Institute for Petrochemical Synthesis have suggested a unique and efficient solution to the problem having split it into two parts. To ensure that the remedy gets into the blood out of the pill, it is required that the remedy slipped `safely` through the stomach - this is stage one. Then it is necessary to make sure that the remedy gets into the blood in the small intestines quicker than the enzymes would destroy it - this is stage two.

The first part of the problem can be solved easily. It is sufficient to cover the pill with a layer that is resistant to the stomach ferments action and dissolves once the pill gets into the intestine. Quite harmless polyacrylic or polymethacrylic acid suits this purpose, therefore the researchers have proposed to use it as a coating. However, in such case insulin will not `live` long enough - it will be destroyed by the enzymes earlier than it gets through the intestine walls. At this stage works the major specificity that differs the pills from all the previous remedy forms applied.


The researchers have suggested that the pills should be made of the pressed little grains of hydrogel, where three substances are introduced. The first substance is insulin per sei. It is not chemically bound with the hydrogel and therefore can be easily released. The second substance is an inhibitor which protect insulin against the enzymes. To ensure that the inhibitor does no harm to the organism, it is made chemically bound with the hydrogel. Thus it will react only with those enzyme molecules which try to penetrate into the hydrogel grain and to `eat up` the insulin from its surface. The hydrogel is indigestible by a human organism, so the bound inhibitor will not get into the blood and leave the organism in a natural way with the hydrogel grains.

And finally, it is necessary to retain the hydrogel grains near the intestine wall so that the insulin protected by the inhibitor against the enzyme attack could stick to the mucous membrane of the intestines and successfully get into the blood. Some `anchor` is required to achieve this. The scientists have proposed to use some polysaccharide as an anchor, the polysaccharide also being chemically bound with the hydrogel. The point is that the intestine wall contains the so-called lectins - the substances which interact with sugars. The lectins are quite capable of binding with polysaccharides on the surface of the hydrogel grains and holding them attached to the mucous membrane.

The last thing to do was to introduce three types of compounds into the hydrogel, namely insulin, enzyme inhibitor and polysaccharide serving as an anchor. However, the developers and patent holders have come to the conclusion that the process can be simplified - it is required to find a substance which could fulfil two functions simultaneously - of an `anchor` and of an inhibitor.

The scientists suggested that the ovomucoid glycoprotein could play this role. This compound seems to be deliberately created for this purpose by nature. The ovomucoid happens to consist of two parts. The protein part is responsible for the enzyme binding, and the carbohydrate part reacts with lectins of the mucuous membrane. The scientists have assumed that the ovomucoid should be added to the hydrogel containing insulin.

As a result the researches have produced the insulin pills based on the hydrogel containing the chemically immobilized ovomucoid. The pills were initially tried on animals - rabbits, mice and rats. Since the results were rather promising, it was decided to proceed with clinical trials of the pills - the pills could not do any harm, but their efficiency should be proved.

The pills are currently undergoing the second stage of the clinical trial and the results are very convincing. Judging by the glucose and insulin concentration in the blood, the perroral intake ensures the same effect as the insulin injection directly into the blood.

"Our drug produces the same effect as traditional injections. The pill should also be taken four times a day, about half an hour before the meal. Of course, the drug does not eliminate the problem completely, it does not cure the patient, what it does - it relieves the patient 4 injections a day. No other remedy has succeeded to achieve that so far," says Professor L. I. Valuyev, one of the drug developers. The scientists called the drug `RANSULIN`, the name originates from the Russian abbreviation for the Russian Academy of Sciences and insulin.

Apparently the way from the clinical trials to the pharmacies can take several years. However, this is only a matter of time, since the efficiency of perroral insulin developed by the Russian scientists gives rise to no doubts.

Tatiana Pitchugina | alphagalileo

More articles from Health and Medicine:

nachricht A chip placed under the skin for more precise medicine
27.05.2015 | Ecole Polytechnique Fédérale de Lausanne

nachricht Mental health care access for teens improving, but less for communities with disparities
27.05.2015 | University of Michigan Health System

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Advance in regenerative medicine

The only professorship in Germany to date, one master's programme, one laboratory with worldwide unique equipment and the corresponding research results: The University of Würzburg is leading in the field of biofabrication.

Paul Dalton is presently the only professor of biofabrication in Germany. About a year ago, the Australian researcher relocated to the Würzburg department for...

Im Focus: Basel Physicists Develop Efficient Method of Signal Transmission from Nanocomponents

Physicists have developed an innovative method that could enable the efficient use of nanocomponents in electronic circuits. To achieve this, they have developed a layout in which a nanocomponent is connected to two electrical conductors, which uncouple the electrical signal in a highly efficient manner. The scientists at the Department of Physics and the Swiss Nanoscience Institute at the University of Basel have published their results in the scientific journal “Nature Communications” together with their colleagues from ETH Zurich.

Electronic components are becoming smaller and smaller. Components measuring just a few nanometers – the size of around ten atoms – are already being produced...

Im Focus: IoT-based Advanced Automobile Parking Navigation System

Development and implementation of an advanced automobile parking navigation platform for parking services

To fulfill the requirements of the industry, PolyU researchers developed the Advanced Automobile Parking Navigation Platform, which includes smart devices,...

Im Focus: First electrical car ferry in the world in operation in Norway now

  • Siemens delivers electric propulsion system and charging stations with lithium-ion batteries charged from hydro power
  • Ferry only uses 150 kilowatt hours (kWh) per route and reduces cost of fuel by 60 percent
  • Milestone on the road to operating emission-free ferries

The world's first electrical car and passenger ferry powered by batteries has entered service in Norway. The ferry only uses 150 kWh per route, which...

Im Focus: Into the ice – RV Polarstern opens the arctic season by setting course for Spitsbergen

On Tuesday, 19 May 2015 the research icebreaker Polarstern will leave its home port in Bremerhaven, setting a course for the Arctic. Led by Dr Ilka Peeken from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) a team of 53 researchers from 11 countries will investigate the effects of climate change in the Arctic, from the surface ice floes down to the seafloor.

RV Polarstern will enter the sea-ice zone north of Spitsbergen. Covering two shallow regions on their way to deeper waters, the scientists on board will focus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International symposium: trends in spatial analysis and modelling for a more sustainable land use

20.05.2015 | Event News

15th conference of the International Association of Colloid and Interface Scientists

18.05.2015 | Event News

EHFG 2015: Securing health in Europe. Balancing priorities, sharing responsibilities

12.05.2015 | Event News

 
Latest News

A chip placed under the skin for more precise medicine

27.05.2015 | Health and Medicine

Linking superconductivity and structure

27.05.2015 | Physics and Astronomy

Mental health care access for teens improving, but less for communities with disparities

27.05.2015 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>